Dear Editor, Patients infected with the 2009 H1N1 pandemic influenza virus often develop severe viral pneumonia with acute respiratory distress syndrome (ARDS) and multiple organ failure. High-dose oseltamivir (C150 mg twice daily) has been advocated as optimal treatment [1] . However, the scientific evidence for this advice is lacking thus far [2] . Therefore, we explored the pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate in critically ill patients with H1N1 pandemic influenza following different dosing regimens.
All patients with H1N1 pandemic influenza admitted to the ICU of the University Medical Center Utrecht were eligible for inclusion. Patients received oseltamivir at a dose determined by their treating physician, and blood samples were drawn at t = 0, 1, 2, 3, 4 and 8 h on day three of treatment. Oseltamivir and oseltamivir carboxylate plasma concentrations were determined by HPLC-MS/MS [3] . The area under the concentration-time curve from 0 to 8 h (AUC 0-8 ) was estimated using noncompartmental analysis. Patient characteristics were obtained from the patient files.
Six patients were included in the analysis (Table 1 ). All patients had ARDS due to H1N1 pneumonitis. Additionally, patient 1 had a pulmonary embolism, patient 2 had kidney failure caused by multiple renal cysts and received continuous venovenous hemofiltration (CVVH; blood flow 200 mL/min, ultrafiltrate flow 2 L/h), patient 3 had received stem cell transplantation and suffered from pulmonary aspergillosis, patient 4 was 29 weeks pregnant (a cesarean section was performed a few hours before sampling), patient 5 was on extracorporeal membrane oxygenation, and patient 6 had newly diagnosed hairy cell leukemia and renal failure for which CVVH was started the day after sampling. The pharmacokinetic parameters, as well as the prescribed dose, were widely variable (Table 1) . No relationship was observed between dose and AUC 0-8 .
Thus far, no concentrationresponse relationship has been established for oseltamivir. However, a carboxylate AUC of [2,270 ng h/mL is considered adequate [4] . Despite a high variability, all carboxylate AUC 0-8 in this study were [2,270 ng h/mL. In line with 
